Quick access list of connected projects
A number of additional projects from across the UK are building on the core EAVE II study.
To find out more about what incorporated and associated projects are, visit:
Developing and Validating a Risk Prediction Model for Long COVID-19
The 'Developing and Validating a Risk Prediction Model for Long COVID-19' study aims to form a risk prediction model to identify who is at greater risk of developing Long COVID.
Read more on the Long COVID research page
Rapid Outcomes of COVID therapeutics in Eave II (ROCOVE)
The ROCOVE project will evaluate the uptake, safety, and effectiveness of monoclonal antibody and antiviral therapy for COVID-19.
Vaccine Breakthrough Project
Using the EAVE II cohort to investigate the effectiveness of currently administered or future approved vaccines by dose, viral variants and patient clinical and demographic characteristics.
Ongoing project investigating the COVID-19 Health Impact on Long-term Child Development in Scotland (CHILDS).
Ongoing study looking to provide provide both the UK and the devolved governments (Scotland, Northern Ireland, Wales) with the information necessary to actionably improve COVID-19 vaccine uptake and coverage.
This study is being lead in a joint partnership between the University of Edinburgh and the Health Data Research UK -BHF Data Science Centre.
COVID-19 in Pregnancy in Scotland (COPS)
The COVID-19 in Pregnancy in Scotland (COPS) study aims to find out how COVID-19 infection during pregnancy affects mothers and babies.
This study is co-led by Dr Sarah Stock and Dr Rachael Wood.
Read more on the COVID-19 in Pregnancy in Scotland study website
National Core Study - Data and Connectivity: COVID-19 Vaccines Pharmacoviligance (DaC-VaP)
EAVE II is involved in the National Core Study - Data and Connectivity: COVID-19 Vaccines Pharmacoviligance (DaC-VaP) study.
This is a UK-wide study looking at the safety and effectiveness of COVID-19 vaccines.
The impact of COVID-19 vaccines in pregnancy, children and young people, and vulnerable groups (DaC-VaP-2)
EAVE II is involved in the The impact of COVID-19 vaccines in pregnancy, children and young people, and vulnerable groups (DaC-VaP-2) study.
Awarded through a funding call by Health Data Research UK and the Alan Turing Institute, and led by Professor Aziz Sheikh, this project works to use UK-wide data to study the uptake, safety and effectiveness of COVID-19 vaccines.
QCovid® is a clinical decision tool intended to support conversations between clinically trained professionals and patients about COVID-19 risk. QCovid was developed by the University of Oxford, and was partially validated using data from the EAVE II cohort.